Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体
This anti-CTLA-4 (Ipilimumab Biosimilar) antibody is a 小鼠 单克隆 antibody detecting CTLA-4 (Ipilimumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体 (ABIN7200671)
抗原
CTLA-4 (Ipilimumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
小鼠
克隆类型
单克隆
标记
This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
-
-
原理
- Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
-
特异性
- The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
-
产品特性
- Recombinant fully human IgG1 monoclonal antibody.
-
纯化方法
- Protein A affinity column
-
纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
-
过滤
- 0.2 μm filtered
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
-
免疫原
- The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
-
亚型
- IgG1 kappa
-
-
anti-CTLA-4 (Ipilimumab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Human Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 mg/mL
-
缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
-
储存液
- Without preservative
-
注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
-
储存条件
- -20 °C
-
储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
有效期
- 12 months
-
-
- CTLA-4 (Ipilimumab Biosimilar)
-
物质类
- Biosimilar
-
背景
-
What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
抗原
-
You are here:
